The field has also seen an increase in tumor-agnostic therapy approvals linked to predictive biomarkers, including NTRK1/2/3 and RET fusions, BRAF V600E mutations, as well as genomic signatures for microsatellite instability (MSI) and tumor mutational burden (TMB) to identify patients who may benefit from immunotherapies. The gene discussed is RET; the disease is neoplasm.